ABSTRACT
Kidney disease is characterised by the improper functioning of the kidney as a result of kidney damage caused by hyperglycaemia-induced oxidative stress. The moderate hyperglycaemia seen in prediabetes can be treated using a combination of metformin and lifestyle interventions (low-calorie diets and exercising). However, patients have been reported to over-rely on pharmacological interventions, thus decreasing the efficacy of metformin, which leads to the development of type 2 diabetes mellitus (T2DM). In this study, we investigated the effects of a rhenium (V) compound in ameliorating renal dysfunction in both the presence and absence of dietary modification. Kidney function parameters, such as fluid intake and urine output, glomerular filtration rate (GFR), kidney injury molecule (KIM 1), creatinine, urea, albumin and electrolytes, were measured after 12 weeks of treatment. After treatment with the rhenium (V) compound, kidney function was restored, as evidenced by increased GRF and reduced KIM 1, podocin and aldosterone. The rhenium (V) compound ameliorated kidney function by preventing hyperglycaemia-induced oxidative stress in the kidney in both the presence and absence of dietary modification.
Subject(s)
Diabetes Mellitus, Type 2 , Hyperglycemia , Kidney Diseases , Metformin , Prediabetic State , Rhenium , Rats , Animals , Hyperglycemia/complications , Hyperglycemia/drug therapy , Uracil/pharmacology , Ligands , Glomerular Filtration Rate , Kidney , Prediabetic State/drug therapy , Metformin/pharmacology , DietABSTRACT
Herein, we report the DNA interaction studies of rhenium(I) and -(V) compounds with Schiff base chelates encompassing biologically relevant moieties. More specifically, the DNA interaction capabilities of these rhenium complexes were probed using Gel Electrophoresis and Calf Thymus-DNA titrations monitored by temperature-controlled electronic spectroscopy. The DNA binding modes of the metal compounds were corroborated by molecular docking simulations. In addition, the synthesis and characterization of a novel facial tricarbonyl rhenium(I) compound, fac-[Re(chrs)(CO)3Br], (chrs = {3-{[(2-hydroxyphenyl)imino]methyl}-4H-chromen-4-one) are reported.
